ライフサイエンスコーパス: non-carrier

1 (5.8%) "long-term carriers" and 530 (80.8%) "non-carrier".

2 l", "short-term", "long-term" carrier or as "non-carrier".

3 (standardized beta = -0.319 for carriers vs. non-carriers).

4 29 with variant status known (59 carriers/70 non-carriers).

5 gruous and incongruous trials were larger in non carriers.

6 y pathogenic variants was similar to that of non-carriers.

7 gin to diverge between mutation carriers and non-carriers.

8 ly symptomatic mutation carriers relative to non-carriers.

9 e at risk of PD that is greater than that of non-carriers.

10 0.028 and 0.08, respectively) as compared to non-carriers.

11 ndent genome-wide signatures than cancers in non-carriers.

12 tion (carriers, mean age=38) whereas 22 were non-carriers.

13 ad higher CB1 receptor binding compared with non-carriers.

14 ecreased in risk carriers when compared with non-carriers.

15 (mean baseline EYO -9.6 years) while 27 were non-carriers.

16 per mmol/L decrease in LDL cholesterol than non-carriers.

17 E280A mutation carriers than in age matched non-carriers.

18 ded: 20 PSEN1 E280A mutation carriers and 24 non-carriers.

19 tors for myocardial infarction compared with non-carriers.

20 tia, asymptomatic carriers, and asymptomatic non-carriers.

21 correctly classifying epsilon4 carriers from non-carriers.

22 sma Abeta(1-42) concentrations (p=0.01) than non-carriers.

23 have mean adiponectin levels that are 19% of non-carriers.

24 e 1976 to 1986 (P = 0.028) compared with the non-carriers.

25 -50.1) more likely to be affected by PD than non-carriers.

26 de earlier in heterozygotes than in mutation non-carriers.

27 ele possibly at decreased risk compared with non-carriers.

28 available for 242 mutation carriers and 262 non-carriers.

29 ptomatic mutation carriers compared to seven non-carriers.

30 n the first-degree relatives of carriers and non-carriers.

31 nd 20% higher triglycerides (P = 0.025) than non-carriers.

32 uencing verified 13 mutation carriers and 16 non-carriers.

33 at the age of 45 years was 31% versus 75% in non-carriers.

34 12Ala variant allele-carriers compared with non-carriers.

35 e carriers, whereas 10 were determined to be non-carriers.

36 th age, as carriers die earlier in life than non-carriers.

37 gton's disease mutation carriers and 32 were non-carriers.

38 ations in PSEN1, PSEN2, or APP, and 134 were non-carriers.

39 tive benefit in APOE4 carriers compared with non-carriers.

40 subtype was more common among APOE epsilon4 non-carriers.

41 y >=2%) were propensity-score matched 1:1 to non-carriers.

42 eletion and duplication carriers compared to non-carriers.

43 2.1) in SJLIFE and 2.1% (1.7-2.5) in CCSS in non-carriers.

44 e were compared between variant carriers and non-carriers.

45 s had a 10-fold risk of developing PD versus non-carriers.

46 man brains from APOE4 carriers compared with non-carriers.

47 Alzheimer's disease mutation carriers and 76 non-carriers.

48 icantly lower plasma EFV concentrations than non-carriers.

49 rs across age, while it declined in familial non-carriers.

50 were higher in mutation carriers compared to non-carriers.

51 duals defined as persistent, intermittent or non-carriers.

52 44 GRN, 24 MAPT and 1 TARDBP) and 57 healthy non-carriers.

53 terns specific to APOE epsilon4 carriers and non-carriers.

54 -encoding strains were 5.3%, versus 0.57% in non-carriers.

55 lated symptoms relative to familial mutation non-carriers.

56 clinical features between LRRK2 carriers and non-carriers.

57 allergy at 60 months as compared to 12.7% of non-carriers.

58 mptomatic and symptomatic groups relative to non-carriers.

59 n E gene (APOE) epsilon 4 variant (epsilon4) non-carriers.

60 ld more common in Pi*ZZ carriers compared to non-carriers.

61 cores 2.0 versus 0.4; P < 0.001) compared to non-carriers.

62 a mutation in GRN, C9orf72, or MAPT, and 127 non-carriers.

63 ed age of symptom onset in carriers, but not non-carriers.

64 2 had lower SU concentrations as compared to non-carriers.

65 tein and chitotriosidase activity to that of non-carriers.

66 n tumour tissue of G84E variant carriers and non-carriers.

67 d altered amygdala function as compared with non-carriers.

68 rriers of the Asp358Ala minor allele than in non-carriers.

69 er, MAF = 0.01%), who weighed 7 kg more than non-carriers.

70 01; P-value=2.8 x 10(-02)) compared with the non-carriers.

71 , GRN, and C9orf72 mutation carriers and 123 non-carriers.

72 e looked on average up to 2 years older than non-carriers.

73 01; P-value=2.8 x 10(-02)) compared with the non-carriers.

74 n had higher cortical Abeta-plaque-load than non-carriers.

75 lopian tube in BRCA1/2 mutation carriers and non-carriers.

76 mporal and parietal (18)F-AV1451 uptake than non-carriers.

77 ptoms differed between mutation carriers and non-carriers.

78 exons of PARK2 have greater risk of PD than non-carriers.

79 (40 symptomatic and 78 asymptomatic) and 102 non-carriers.

80 disease, had higher enzymatic activity than non-carriers (13.69 micromol/l/h versus 11.93 micromol/l

81 elevated CSF MMP2 levels compared to that of non-carriers (13168 vs 9472 pg/mL, p = 0.01).

82 generation in 15 cognitively normal mutation non-carriers, 20 asymptomatic carriers, and 15 symptomat

83 ational prospective cohort study, 24 APOE e4 non-carriers, 22 heterozygotes and 20 homozygotes in the

84 (from 76% to 27%) to levels similar to APOE4 non-carriers (27.14%), which strongly indicate protectio

85 est Z score differences between carriers and non-carriers 5 years before expected onset in tests of n

86 nt differences between mutation carriers and non-carriers 5 years before expected onset, when differe

87 ively asymptomatic mutation carriers than in non-carriers (5% versus 17%, P = 0.014) and the odds of

88 thic PD, 40 LRRK2-PD, 70 GBA-PD, 196 healthy non-carriers, 55 LRRK2-NMC and 97 GBA-NMC participated i

89 lower enzymatic activity than GBA and LRRK2 non-carriers (7.88 micromol/l/h versus 11.93 micromol/l/

90 atic carriers (9 pg/mL [6-13]; p<0.0001) and non-carriers (8 pg/mL [6-11]; p<0.0001), and was higher

91 arriers (1003 pg/mL (624-1358), p<0.001) and non-carriers (990 pg/mL (597-1373), p<0.001) (corrected

92 ein E epsilon4 gene (APOE4) heterozygotes or non-carriers.A group of UK neurologists, old age psychia

93 found to smoke fewer cigarettes per day than non-carriers (AA P = 6.6 x 10(-5), EA P = 0.021).

94 tion of a diaryliodonium salt precursor with non-carrier-added (18)F-fluoride, yielded a product with

95 matic carriers, presymptomatic carriers, and non-carriers, adjusting for age and sex.

96 ld (95% CI=0.74-3.00) for ALS-G, compared to non-carriers after adjusting for SNPs 6 and 9.

97 .52, 1.25-1.85; p=1.74x10(-5)) compared with non-carriers after lobar ICH.

98 ificantly shorter sleep duration compared to non-carriers after the adjustment for individual proport

99 age 58.3 +/- 7.7 years, four females) and 14 non-carriers (age 60.8 +/- 6.9 years, four females), and

100 Among non-carriers alone, variation in RBC hydration, membrane

101 lood of 34 FTLD expansion carriers, 166 FTLD non-carriers and 103 controls.

102 up (compared with 59 [26.6%] of 222 HLA-A*03 non-carriers and 13 (17.1%) of 76 HLA-A*03 heterozygotes

103 imaging measures at baseline in 131 mutation non-carriers and 143 preclinical autosomal dominant Alzh

104 p (compared with 162 [63.8%] of 254 HLA-A*03 non-carriers and 40 [55.6%] of 72 HLA-A*03 heterozygotes

105 ial and follow-up examinations compared with non-carriers and continued to develop nevi rather than s

106 with individuals with other genotypes (both non-carriers and heterozygous carriers).

107 vi rather than show nevus regression seen in non-carriers and spouse controls.

108 increased in mutation carriers compared with non-carriers and spouse controls.

109 requent in APOE varepsilon4 carriers than in non-carriers and that A(+)N(+) was more, and A(+)N(-) le

110 mpared between genotyped I1307K carriers and non-carriers and their first-degree relatives.

111 n carriers (ie, BRCA-positive women), tested non-carriers and untested participants (ie, BRCA-negativ

112 eposition is reduced by up to 43.5% in APOE4 non-carriers and up to 55.6% in APOE4 carriers, accordin

113 (either presymptomatic mutation carriers or non-carriers), and had at least two serum samples with a

114 yloid positive at an earlier age compared to non-carriers, and greater e4 dosage was associated with

115 ave 50% greater risk of prostate cancer than non-carriers, and homozygotes have more than double the

116 rs endorsed less mood symptoms compared with non-carriers, and worse everyday skills.

117 loci comparing effective allele carriers to non-carriers are 21.48 (95% confidence interval=11.13-41

118 eus have a CST dominated by S. aureus, while non-carriers are distributed across the other six CSTs.

119 Remarkably, DRB1*07:01 non-carriers are younger, more commonly female and exper

120 have greater risk of nicotine addiction than non-carriers as assessed by the Fagerstrom Test for Nico

121 d carriers of Aa could be discriminated from non-carriers (AUC = 0.78, P <0.0001).

122 tion 2 hours after an oral glucose load than non-carriers (beta = 0.43 mmol l(-1), P = 5.3 x 10(-5)).

123 s higher in both mutation groups compared to non-carriers (both P < 0.001).

124 a42 levels were significantly different from non-carriers but did not differ between preclinical muta

125 nd decreases in PiB SUVR occurred in APOE e4 non-carriers but not carriers.

126 more common in LP/P variant carriers than in non-carriers but was present in less than half of carrie

127 and memory-guided attention was observed in non-carriers, but this correlation was not significant i

128 lasma melatonin measurements, as compared to non-carriers (by 12 and 11 min, respectively; accounting

129 matic C9orf72 mutation carriers (C9+) and 29 non-carriers (C9-)) were included in the present cross-s

130 Compared with non-carriers, carriers had greater right hippocampal and

131 Patients were grouped into non-carriers, carriers of 'non-pathogenic' GBA1 variants

132 [homozygotes] vs 75% [heterozygotes] vs 69% [non-carriers]; Cochran-Armitage trend test p=0.0587).

133 IMPACT study, who were included in all three non-carrier cohorts.

134 2) and 268 family members without mutations (non-carrier control group).

135 nd in order to boost the sample size for the non-carrier control groups, we randomly selected 134 non

136 s 0.5%; p=0.011) and MSH6 carriers than MSH6 non-carrier controls (3.0% vs 0%; p=0.034).

137 mL, was higher in MSH2 carriers than in MSH2 non-carrier controls (4.3% vs 0.5%; p=0.011) and MSH6 ca

138 PMC; 34 MAPT, 70 GRN and 64 C9ORF72) and 173 Non-carrier Controls (NC)].

139 tages, discriminating mutation carriers from non-carrier controls 10-20 years before the estimated on

140 s of MSH2, and 135 carriers of MSH6] and 184 non-carrier controls [65 non-carriers of MLH1, 76 non-ca

141 r's disease, 18 asymptomatic carriers and 21 non-carrier controls underwent diffusion tensor magnetic

142 omatic C9orf72 HRE carriers, 39 asymptomatic non-carrier controls, 19 people with sporadic ALS, 10 wi

143 and BRCA2 germline mutation carriers and in non-carrier controls, and in sporadic DCIS.

144 ch in healthy aging through inclusion of the non-carrier controls.

145 of prostate cancer compared with age-matched non-carrier controls.

146 (34 presymptomatic, 19 symptomatic) and 183 non-carrier controls.

147 tomatic C9orf72 HRE carriers and age-matched non-carrier controls.

148 % for pre-weaning mortality when compared to non-carrier dam and sire matings.

149 tly poorer cumulative survival compared with non-carrier DCM patients: event-free survival at the age

150 n TREM2-R47H and TREM2-R62H carriers than in non-carriers, demonstrating a TREM2 requirement in both

151 In addition, in epsilon4 non-carriers diagnosed with AD or mild cognitive impairm

152 was 0.80% in mutation carriers and 0.84% in non-carriers; difference -0.04, SE 0.02) followed by the

153 volume 8.1% in mutation carriers and 8.3% in non-carriers; difference -0.2, SE 0.1).

154 er heads in increaser-allele carriers versus non-carriers during mid-childhood, suggesting a previous

155 ed psychopathology in mutation carriers over non-carriers during the presymptomatic stage, suggesting

156 tes (E4/E4), 20 heterozygotes (E3/E4) and 20 non-carriers (E3/E3) - to determine effect on memory-gui

157 ed difference among 50,060 KIF6 carriers and non-carriers enrolled in 8 randomized trials of statin t

158 three fluid cognitive domains compared with non-carriers, especially for memory (beta = -0.234, p <

159 gnitive decline in APOE4 carriers but not in non-carriers, even after controlling for amyloid-beta an

160 perception of their current health than did non-carriers, even though they had been told that carrie

161 In crossover experiments, individual non-carrier ewes had lambs that experienced fatal pneumo

162 minant Alzheimer's disease mutations and 169 non-carrier familial controls from the DIAN study were i

163 nt Alzheimer's disease genetic mutations and non-carrier familial controls recruited in Australia, Eu

164 uantitative measure to compare probands with non-carrier family members rather than a qualitative, di

165 An intermediate nevus phenotype in non-carrier family members suggests the presence of addi

166 ies, including penetrants, non-penetrants or non-carriers for NSCLP.

167 ations were higher in mutation carriers than non-carriers from 16 years prior to estimated symptom on

168 ier control groups, we randomly selected 134 non-carriers from the BRCA1 and BRCA2 cohort of the IMPA

169 enilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention I

170 ) E280A (Glu280Ala) mutation and age-matched non-carriers from the Colombian autosomal dominant Alzhe

171 deletion and 12 duplication carriers to 6882 non-carriers from the large-scale brain Magnetic Resonan

172 APOE4 carriers (group 1, n = 27), AB+ APOE4 non-carriers (group 2, n = 29), and AB- normal controls

173 enotypic differences between carriers versus non-carrier groups are observable.

174 The carrier and non-carrier groups did not differ significantly in their

175 ered significantly among the groups (APOE e4 non-carriers>heterozygotes>homozygotes).

176 APOE-epsilon4 carriers relative to non-carriers had a lower macromolecular proton fraction

177 rriers (51 MAPT, 92 GRN, 88 C9orf72) and 145 non-carriers had available longitudinal data at a follow

178 Four of the 13 mutation carriers and one non-carrier have developed invasive melanoma.

179 d subsequent Alpha variant waves compared to non-carriers (hazard ratio = 0.63, 0.42-0.93, P = 0.02).

180 Comparing C282Y homozygotes with non-carriers, hazard ratios were 1.72 (95% confidence in

181 ptomatic carriers) and 30 healthy relatives (non-carrier healthy controls) were assessed with a visua

182 d symptoms of FXTAS over time as compared to non-carrier healthy controls, suggesting a potential rol

183 esent in premutation carriers as compared to non-carrier healthy controls.

184 tly enriched in V122I carriers compared with non-carriers (HR = 2.8, 95% CI 1.7-4.5, p = 2.6 x 10(-5)

185 testinal paracellular (IP), cellular passive non-carrier (ICNC), cellular passive carrier-mediated (I

186 owed significantly higher PIB retention than non-carriers in all brain regions except the hippocampus

187 biomarkers in mutation carriers compared to non-carriers in autosomal dominant Alzheimer's disease.

188 sociated CNVs showed poorer performance than non-carriers in immediate (P = 0.0036) and delayed (P =

189 velop AD have a thinner cerebral cortex than non-carriers in regions known to be affected by typical

190 in clinical benefit among KIF6 carriers and non-carriers in response to therapies that lower LDL cho

191 enefit among KIF6 719Arg allele carriers and non-carriers in response to therapies that reduce LDL ch

192 ilon2 allele had larger ICH volumes than did non-carriers in the discovery phase (p=2.5x10(-5)), in b

193 ite matter between FAD mutation carriers and non-carriers in the preclinical (clinical dementia ratin

194 APOE e4 carriers had greater magnitudes than non-carriers in the rates of change for all CSF biomarke

195 Tau-first APOE epsilon4 non-carriers, in contrast, recapitulated many of the fea

196 ed with earlier mortality in comparison with non-carriers, independent of the development of dementia

197 [Formula: see text]-Thalassemia carrier and non-carriers is handled by Synthetic Minority Oversampli

198 When compared with non-carriers, LDLR mutation carriers had higher plasma L

199 h consecutive pneumococcal carriage outcome (non-carrier, low-dense and high-dense pneumococcal carri

200 of 0.8-2.5 Mb duplications spanning STS, and non-carrier male (n = 192, 826) and female (n = 227, 235

201 riers performed significantly less well than non-carriers, matched for age and IQ, on tests of attent

202 3K1-rs889312 were significantly shorter than non-carriers (mean height 162.4 cm [95% CI 162.1-162.7]

203 ers (mean SUVr difference -0.06), but not in non-carriers (mean SUVr difference 0.02).

204 s (mean SUVr difference of 0.09), but not in non-carriers (mean SUVr difference 0.02; P = 0.005).

205 f patients without molecular diagnoses (i.e. non-carriers, median 46.0 years).

206 alasin B inhibited absorption by 92 +/- 7 %; non-carrier-mediated transport is therefore minimal.

207 % in C282Y homozygous men, and 0.60-4.80% in non-carrier men.

208 Compared with non-carriers, mutation carriers were younger at onset an

209 We found that in the normal breast of non-carriers, myoepithelial cells frequently co-express

210 GRN or MAPT mutation carriers (n = 107) and non-carriers (n = 113), using general linear mixed-effec

211 n = 164) from mutation carriers (n = 33) and non-carriers (n = 42) in a Swedish cohort of autosomal d

212 = 0.024) were decreased relative to that of non-carriers (n = 8).

213 ts in PSEN1, PSEN2, and APP genes (n=155) or non-carriers (n=93).

214 ic and symptomatic FAD mutation carriers and non-carrier (NC) relatives.

215 mutation carriers (MCs) and 110 asymptomatic non-carriers (NCs).

216 ntly younger ages at the onset compared with non-carriers (NeuroX: 56.4 vs. 61.4 years; exome: 38.5 v

217 ptomatic mutation carriers was lower than in non-carriers (odds ratio = 0.50, 95% confidence interval

218 an unfavourable outcome compared with 33% of non-carriers of APOE epsilon4.

219 plaque and tangle load between carriers and non-carriers of BCHE-K still failed to disclose a relati

220 d less frequently male (47%, p=0.044), while non-carriers of both DRB1*07:01 and DRB1*04:02 experienc

221 s of apo(a) were higher in the carriers than non-carriers of both rs10455872 and rs3798220.

222 rs of MSH6] and 184 non-carrier controls [65 non-carriers of MLH1, 76 non-carriers of MSH2, and 43 no

223 arrier controls [65 non-carriers of MLH1, 76 non-carriers of MSH2, and 43 non-carriers of MSH6]), and

224 ers of MLH1, 76 non-carriers of MSH2, and 43 non-carriers of MSH6]), and in order to boost the sample

225 of LPA mRNA were higher in the carriers than non-carriers of rs10455872 (P = 0.0001) and were not dif

226 and were not different between carriers and non-carriers of rs3798220.

227 and fifty-nine of which included carrier and non-carriers of the APOE epsilon4 gene, those at highest

228 (AUC 0.86 [95% CI 0.72-0.94]) carriers from non-carriers of the same age and sex.

229 (AUC 0.86 [95% CI 0.72-0.94]) carriers from non-carriers of the same age and sex.

230 d not perform significantly more poorly than non-carriers on any of the background tests, on any of t

231 carriers declined slightly more rapidly than non-carriers on most cognitive measures, with processing

232 sma NfL to discriminate between carriers and non-carriers only reached high sensitivity close to the

233 nses in the low-density carriers compared to non-carriers or high-density carriers.

234 le with >50 repeats, and was not detected in non-carriers or individuals with an intermediate allele

235 eas no significant decreased was observed in non-carriers (P >0.0125).

236 E e4 carriers and most slowly in men APOE e4 non-carriers (p < 0.001).

237 AB42:38 in PSEN1 versus APP (P < 0.001) and non-carriers (P < 0.001); higher AB38:40 in APP versus P

238 AB38:40 in APP versus PSEN1 (P < 0.001) and non-carriers (P < 0.001); while AB42:40 was higher in bo

239 0.4 versus a mean thinning of 76.8 +/- 22 in non-carriers (p = 0.015).

240 from biallelic MUTYH carriers compared with non-carriers (p = 2 x 10(-23) and p = 6 x 10(-11), respe

241 antly higher in FTLD expansion carriers than non-carriers (P = 7.8E-13).

242 cognitive domain in APOE varepsilon4 allele non-carriers (P<0.01).

243 2 Gly2019Ser homozygotes, heterozygotes, and non-carriers (p=0.85).

244 s was significantly worse (83% versus 96% in non-carriers, P = 4.8 x 10(-3)).

245 fest neuropsychiatric phenotypes compared to non-carrier parents (P = 0.037, OR = 6).

246 tion in GRN, C9orf72 or MAPT, and 70 healthy non-carriers participating in the Genetic Frontotemporal

247 atrophy patterns in C9orf72 carriers versus non-carriers, patient groups showed topographically simi

248 Compared with non-carriers, plasma p-tau181 concentration was higher i

249 Relative to biologically related non-carriers, preclinical MAPT carriers endorsed worse m

250 Compared to non-carriers, presymptomatic presenilin 1 mutation carri

251 matic mutation carriers, and 20 asymptomatic non-carriers, ranging in age from 20 to 56 years.

252 women, comparing variant allele carriers to non-carriers, reduced breast cancer risk was associated

253 autoreactive clones compared with those from non-carriers, revealing defective central and peripheral

254 iadochokinesia was more frequent compared to non-carriers (right hand: 3.8% versus 0%; adjusted P = 0

255 The carrier vs non-carrier risk for spermatogenic failure was increased

256 rs are treated or monitored differently from non-carriers, roughly 238 patients would need to be geno

257 Non-carriers showed an intermediate nevus phenotype betw

258 Moreover, transfection of healthy non-carrier sibling OPCs confirmed a pathogenic effect o

259 dominant Alzheimer's disease mutations, and non-carrier siblings (aged 30-61 years) were analysed fo

260 t Alzheimer's disease mutations (n=192), and non-carrier siblings (n=108).

261 ce of inheriting their familial mutation, so non-carrier siblings can be recruited for comparisons in

262 Fibroblasts from ALS8 patients and their non-carrier siblings were successfully reprogrammed to a

263 cognitively normal varepsilon4 carriers and non-carriers simultaneously, (ii) the sensitivity of the

264 eiotic drive genes cause the degeneration of non-carrier sperm to bias transmission in their favour.

265 r (4.22 [2.46-7.24], p<0.001) and DRB1*07:01 non-carrier status (8.39 [1.88-37.44], p=0.005) were ind

266 ed a model carrier isolate (D30) and a model non-carrier strain (930918-3) to identify differential g

267 age specific differences between carrier and non-carrier strains suggesting a role for mobile genetic

268 ited neuropsychiatric symptoms compared with non-carriers that may be considered as future clinical t

269 Compared to APOE epsilon4 non-carriers, the APOE epsilon4 carriers had a 15% highe

270 significantly greater than heterozygotes or non-carriers throughout all 12 regions of interest (P <

271 ne PRKN pathogenic variant were as likely as non-carriers to have Parkinson's disease [odds ratio = 1

272 level in 20 R221S offspring carriers and 20 non-carriers using two alternative antibodies and determ

273 23.6 +/- 2.2 years; 31 NTRK1-T carriers, 360 non-carriers) using 105-gradient diffusion tensor imagin

274 psilon4 carrier[varepsilon4(+)], varepsilon4 non-carrier[varepsilon4(-)]) and brain-derived neurotrop

275 and APOE4 allele count [9.7% (8.8; 10.6) in non-carriers versus 38.4% (36; 40.8) to 60.4% (54; 66.8)

276 APOE4 carriers and during retrieval in APOE4 non-carriers was related to more amyloid and tau, respec

277 Compared to non-carriers, we observed nominally significant positive

278 d HRs comparing BMPR2 mutation carriers with non-carriers were 1.42 (95% CI 1.15-1.75; p=0.0011) for

279 Familial non-carriers were included as healthy controls (n = 165)

280 ApoE epsilon4 carriers and non-carriers were screened for anosmia, severe hyposmia,

281 DRB1*07:01 non-carriers were younger (p=0.005) and less frequently

282 1), and began to differentiate carriers from non-carriers when aged 22 years (22 years before the est

283 ity was reduced in heterozygotes compared to non-carriers when each mutation was compared independent

284 in APOE epsilon4 carriers and APOE epsilon4 non-carriers when evaluated separately.

285 igher in vitro NK cell killing activity than non-carriers whereas those with alleles genetically prot

286 ion of schizophrenia polygenic risk than did non-carriers, which provides a second robust line of evi

287 d GRN mutation carriers relative to familial non-carriers, while smaller volumes were observed in C9o

288 r PINK1 was significantly lower than that of non-carriers, while the age at onset of carriers with ot

289 s (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures

290 ease was significantly higher as compared to non-carriers with a significant interaction between rs10

291 symptomatic from presymptomatic carriers and non-carriers with areas under the curve of 0.84 (95% con

292 1070 PSEN1 E280A mutation carriers and 1074 non-carriers with baseline assessments; of these partici

293 higher risk of death from any cause than did non-carriers with diabetes (hazard ratio 1.94, 95% CI 1.

294 otes with diabetes had higher mortality than non-carriers with diabetes, and 27.3% of all deaths amon

295 nt differences between mutation carriers and non-carriers with regard to absolute age, age relative t

296 sease mutation carriers were compared to 106 non-carriers with regard to frequency of behavioural sym

297 f fibrillar Abeta deposition in carriers and non-carriers with regression analysis and to estimate th

298 ve clinical features compared to young-onset non-carriers, with more postural symptoms at diagnosis a

299 rior parietal lobule in carriers compared to non-carriers, with trend-level effects in the medial tem

300 4.3% in C282Y homozygous women, 0.37-3.0% in non-carrier women, 0.86-6.8% in C282Y homozygous men, an